Investor Presentaiton slide image

Investor Presentaiton

Investor presentation Full year 2018 Slide 121 Enhancing access to affordable medicines is a key priority Product quality and patient safety is material 29.2 million patients reached with diabetes care products 5 million people with diabetes treated at cost below USD 0.16 per day Access to insulin commitment expanded Novo Nordisk guarantees to make low-priced human insulin available in the world's least developed and low-income countries, selected middle-income countries and selected humanitarian relief organisations 103 million DKK donations to World Diabetes Foundation and Novo Nordisk Haemophilia Foundation 3 product recalls O failed inspections 78 countries, home of 124 million people with diabetes 2018/2019 maximum price 4 USD/vial 0.3 million¹ people treated at USD 0.12 per day in average Note: Full social statements to be found in Novo Nordisk Annual Report 2018 changing diabetes® 1 This reflects the people covered by the 'Access to insulin commitment'. novo nordisk
View entire presentation